Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118

NCT01670513 is registered in ClinicalTrials.gov with Dow Pharmaceutical Sciences as lead sponsor.

NCT NCT01670513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01670513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Lead sponsor
Dow Pharmaceutical Sciences
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 30, 2012
Completion date
July 31, 2013
Enrollment
60 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis